Pfizer Inc (PFE)

PFE on New York Consolidated

34.32USD
27 Feb 2015
Change (% chg)

$-0.27 (-0.78%)
Prev Close
$34.59
Open
$34.44
Day's High
$34.66
Day's Low
$34.29
Volume
24,388,891
Avg. Vol
28,478,801
52-wk High
$34.97
52-wk Low
$27.51

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.76
Market Cap(Mil.): $218,380.80
Shares Outstanding(Mil.): 6,300.66
Dividend: 0.28
Yield (%): 3.23

Financials

  PFE Industry Sector
P/E (TTM): 24.45 38.99 40.21
EPS (TTM): 1.42 -- --
ROI: -- 17.01 16.34
ROE: -- 17.53 17.27
Search Stocks

UPDATE 1-Sanofi's new boss could earn more than Total's, less than Pfizer's

PARIS, Feb 20 - Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros ($4.8 million) a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake.

20 Feb 2015

REFILE-US STOCKS-Wall St rises on Greek deal hopes even as energy drops

NEW YORK, Feb 10 - U.S. stocks rose on Tuesday on hopes that Greek debt negotiations could result in a deal that stabilizes Europe although a drop in oil prices limited the advance.

10 Feb 2015

Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co

- Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.

09 Feb 2015

Pfizer in $5 bln accelerated buyback deal with Goldman, Sachs & Co

Feb 9 - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.

09 Feb 2015

Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, February 06 (Fitch) Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating action follows Pfizer's announcement that it will acquire Hospira, Inc. (HSP) for roughly $17 billion which includes approximately $1.7 billion in HSP debt. The rating action applies to approximately $38.9 billion of consolidated debt outstanding as of Sept. 28, 2014. The Rating Outloo

06 Feb 2015

RPT-Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK, Feb 5 - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

06 Feb 2015

Pfizer to buy Hospira for $15 billion to bolster hospital products

By Caroline Humer, Ransdell Pierson, Vidya L Nathan and Natalie Grover | Video

05 Feb 2015

India Morning Call-Global Markets

NEW YORK - U.S. stocks climbed on Thursday as energy shares bounced with oil prices, while news Pfizer Inc would buy Hospira Inc in a massive deal further boosted the market.

05 Feb 2015

Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

05 Feb 2015

Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK, Feb 5 - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

05 Feb 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $102.51 -0.29
Novartis AG (NOVN.VX) CHF97.45 -0.70
Merck & Co., Inc. (MRK.N) $58.54 -0.42
Roche Holding Ltd. (ROG.VX) CHF258.80 -0.20
Abbott Laboratories (ABT.N) $47.37 -0.24
Bayer AG (BAYGn.DE) €132.05 +0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.70 +0.16
AstraZeneca plc (AZN.L) 4,469.50p +4.50
GlaxoSmithKline plc (GSK.L) 1,541.50p -12.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Validea
$12.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks